(PharmaNewsWire.Com, March 16, 2017 ) The Global Plasma Protein Therapeutics Market is estimated to be at USD 19.2 Billion in 2015 and is poised to reach USD 27.56 Billion by 2020 with a CAGR of 7.5%. The use of plasma protein in the medical applications has increased significantly in the recent years. With the advancements in technology, the process for fractionating the protein from plasma has become more cost saving and efficient and is supposed to boost the plasma protein therapeutics market.
According to WHO reports more than half of the global blood donors belong to high income countries which constitutes 18% of the population. With rising awareness among people regarding blood donations and government initiatives, plasma derived medicine market is expected to grow at a significant rate in the coming years.
Plasma is a protein rich fluid and plays a crucial role in clotting and providing immunity to diseases. By isolating the proteins from plasma, they can used for medical therapies including autoimmune, immune deficiencies, neurological and bleeding disorders. Plasma protein therapies are used to treat well-defined medical condition by replacing the deficient or missing proteins in plasma. Plasma protein therapeutics involves biological medicines either infused or injected to treat life-threatening, chronic and genetic diseases.
Increasing introduction of new plasma-derived therapies is the primary driving factor for the market. The market is also driven by a host of other factors, including rising prevalence of life threatening diseases involving immune or neurological systems and other infectious diseases like Rabies, Tetanus, Hepatitis A&B and varicella. On the contrary there are a few restraints for market which includes stringent government policies, issues pertaining to reimbursement, complexity in manufacturing.
The Global Plasma Protein Therapeutics Market is segmented based on product type as Immunoglobulins, Albumin, Coagulation Factors, alpha-1 proteinase inhibitor and others. On the basis of application the market is categorised as Hemophilia, Primary Immunodeficiency Disorder, Idiopathic Thrombocytopenic Purpura, Secondary Immunodeficiency and others. Based on geographical region, the market is analysed in the regions of North America, Europe, Asia-Pacific, Latin America and Middle-East & Africa.
The major players in the plasma protein therapeutic market are Baxter, CSL Behring, Biotest, China Biologics, Grifols, Kedrion, Octapharma, Shire Plc., and Chengdu Inst.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
